Expert commentary: The VERTIS-CV trial | Francesco Giorgino
HTML-код
- Опубликовано: 17 июн 2020
- Francesco Giorgino comments on the findings from the VERTIS-CV trial, and discusses the cardiovascular efficacy and safety of ertugliflozin in the context of the SGLT2 inhibitor class (10:10).
View more on Medicine Matters diabetes: bit.ly/2Y0N8yL Наука